share_log

Chardan Capital Maintains Buy on Regenxbio, Maintains $52 Price Target

Benzinga ·  Mar 14 12:32

Chardan Capital analyst Daniil Gataulin maintains Regenxbio (NASDAQ:RGNX) with a Buy and maintains $52 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 352
Write a comment